USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
09-May-2013
Asia Pacific
Market Research
P704-01-00-00-00
LS00139-AP-MR_16980
The Chinese pharmaceutical market is expected to be the third-largest in the world in 2013. This research service analyzes various aspects of the Chinese pharmaceutical market between 2007 and 2016. Rising income, improving healthcare infrastructure, and insurance systems are some factors that drive this market. The study discusses in detail the market challenges and opportunities, competitive analysis, offers a revenue forecast, and a list of local company profiles along with their revenue.
Executive Summary
Executive Summary—Market Engineering Measurements
Executive Summary—CEO’s Perspective
Market Overview—Segmentation
Market Overview—Key Questions This Study Will Answer
Global Top 10 Pharmaceutical Markets
Market Engineering Measurements
Chinese Pharmaceutical Market—Revenue Forecast
Revenue Forecast Discussion
Market Overview of Chinese Pharmaceutical Market—Financial Status
Market Challenges and Opportunities—Key Challenges for Chinese Pharmaceutical Manufacturers
Market Challenges and Opportunities—Internal Challenges for Pharmaceutical Manufacturers Discussion
Industry Challenges and Opportunities—External Challenges for Pharmaceutical Manufacturers Discussion
Market Challenges and Opportunities—Growth Opportunities for Pharmaceutical Manufacturers
Distribution Trends and Analysis—Pharmaceutical Distribution Integration Forecast
Distribution Trends and Analysis—Pharmaceutical Distribution Integration Forecast Discussion
Distribution Trends and Analysis—Pharmaceutical Supply Forecast Discussion
Competitive Analysis
Competitive Analysis (continued)
Competitive Analysis (continued)
Top Chinese Pharmaceutical Industry Participants
Top Chinese Pharmaceutical Industry Participants (continued)
Company Profile—Guangzhou Pharmaceutical Holdings Ltd.
Company Profile—Xiuzheng Pharmaceutical Group Co., Ltd.
Company Profile—Yangtze River Pharmaceutical Group
Company Profile—Harbin Pharmaceutical Group Holding Co., Ltd.
Company Profile—Shanghai Pharmaceutical Holding Co., Ltd.
Company Profile—China Shijiazhuang Pharmaceutical Group Co., Ltd.
Company Profile—North China Pharmaceutical Group Corporation
Company Profile—China National Pharmaceutical Group Corporation
Company Profile—China National Pharmaceutical Group Corporation (continued)
Company Profile—Northeast Pharmaceutical Group Co. Ltd.
Company Profile—China Resources Double-crane Pharmaceutical Co., Ltd.
Company Profile—Hangzhou East China Pharmaceutical Group Co., Ltd.
Company Profile—Kelun Pharmaceutical Co., Ltd.
Company Profile—Heilongjiang Zhenbao Island Pharmaceutical Co., Ltd.
Company Profile—Kangmei Pharmaceutical Co., Ltd.
Company Profile—Qilu Pharmaceutical Co., Ltd.
Company Profile—Furen Medicine Group Ltd.
Company Profile—Shanghai Fosun Pharmaceutical (Group) Ltd.
Company Profile—China Resources Three Nine Pharmaceutical Co., Ltd.
Company Profile—Reyoung Pharmaceutical Co., Ltd.
Company Profile—Jiangxi Jimin Kexin Pharmaceutical Co., Ltd
Company Profile—Jiangsu Heng Rui Medicine Co., Ltd.
Company Profile—Yunnan Baiyao Group Co., Ltd.
Company Profile—Luye Pharma Group Ltd.
Company Profile—Tianjin Zhongxin Pharmaceutical Group Co., Ltd.
Company Profile—Jiangsu Hansoh Pharmaceutical Co., Ltd.
Company Profile—Heze Ruiying Pharmaceutical Group Co., Ltd.
Company Profile—Zhuhai United Laboratories Pharmaceutical Co., Ltd.
Company Profile—Zhejiang NHU Group Holdings Ltd.
Company Profile—Taiji Group Holdings Ltd.
Company Profile—Lunan Pharmaceutical Group Co., Ltd.
Company Profile—Shandong Luoxin Pharmacy Stock Co., Ltd.
Company Profile—Shandong Luoxin Pharmacy Stock Co., Ltd. (continued)
Company Profile—Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.
Company Profile—Renhe (Group) Development Co., Ltd.
Company Profile—Zhejiang Medicine Co., Ltd.
Company Profile—Wuhan Humanwell Healthcare(Group) Co., Ltd.
Company Profile—Nanjing Pharmaceutical Industry (Group) Co., Ltd.
Conclusions and Recommendations—Game Changing Strategies
Conclusions and Recommendations—Conclusions
Conclusions and Recommendations—Recommendations
Legal Disclaimer
Table of Acronyms Used
Exchange Rate in the Study
Who is Frost & Sullivan
What Makes Us Unique
TEAM Methodology
Our Global Footprint 40+ Offices
Speak directly with our analytics experts for tailored recommendations.
Recent related Life Sciences research
13 Jan 2025 | Global | Market Outlook
Top 6 Growth Opportunities for the Digital Health Industry, 2025
Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...
17 Dec 2024 | Global | Market Research
Cybersecurity in Healthcare, United States, 2024
Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...
12 Dec 2024 | Global | Market Outlook
Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025
Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...
05 Dec 2024 | Global | Frost Radar
Frost Radar™: Enterprise Conversational AI in Healthcare, 2024
This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-care, a...
27 Nov 2024 | Global | Market Research
Generative AI in Payer and Provider IT Transformation, Global, 2024-2029
The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Market Research |
|---|---|
| No Index | Yes |
| Podcast | No |
| WIP Number | P704-01-00-00-00 |
| Is Prebook | No |
Chinese Pharmaceutical Market
$4,950.00
Special Price $3,712.50 save 25 %